Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab plus chemotherapy).

被引：12

作者：

Chan, Jennifer A.

Raj, Nitya Prabhakar

Aggarwal, Rahul Raj

Calabrese, Susan

DeMore, April

Dhawan, Mallika Sachdev

Fattah, Delaire

Fong, Lawrence

Grabowsky, Jennifer

Hope, Thomas A.

Kolli, Kanti Pallav

Munster, Pamela N.

Perez, Kimberly

Reidy, Diane Lauren

Von Fedak, Sofia

Zhang, Li

Bergsland, Emily K.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4148

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4148

引用

页数：2